LuciBelzu 40mg (Belzutifan)

Description:

LuciBelzu 40mg (Belzutifan) is a targeted cancer medicine used to treat certain tumors related to Von Hippel-Lindau (VHL) disease, including renal cell carcinoma (kidney cancer), pancreatic neuroendocrine tumors, and central nervous system hemangioblastomas when surgery is not immediately required. It works by blocking HIF-2α (hypoxia-inducible factor-2 alpha), a protein that helps tumors grow in low-oxygen environments.

Dosage:
The typical recommended dose of LuciBelzu 40mg (Belzutifan) is 120 mg once daily (usually three 40 mg tablets), taken with or without food, or as prescribed by a healthcare professional. Treatment usually continues as long as it remains effective and well tolerated.

Side Effects:

Some patients using LuciBelzu 40mg (Belzutifan) may experience:

• Fatigue
• Headache
• Dizziness
• Nausea
• Anemia (low red blood cell levels)

In some cases, LuciBelzu 40mg may cause low oxygen levels in the blood (hypoxia) or more severe anemia. Patients should contact their doctor if they experience breathing difficulties, extreme fatigue, or unusual symptoms.

Prescribing Information:

Before starting treatment, patients should be properly evaluated for VHL-related tumors or advanced renal cell carcinoma. LuciBelzu 40mg (Belzutifan) should be used under the supervision of an experienced oncology specialist.

Patients should inform their doctor about other medications and should avoid using LuciBelzu 40mg during pregnancy or breastfeeding due to potential risks.

Suggestion:

For best results, take LuciBelzu 40mg (Belzutifan) exactly as prescribed. Do not adjust the dosage or stop treatment without medical advice. Regular monitoring of blood oxygen levels and hemoglobin may be required during treatment.